Caring for patients with CKD?

Talk to your patients about the Moon clinical study.

With limited treatment options in chronic kidney disease, the Moon clinical research study is currently underway to investigate potential treatments. Consider the Moon as an opportunity for your patients with CKD to access emerging treatments.

Moon is a phase III clinical study for adults and adolescents with CKD. This study is evaluating [brief summary of primary objectives].

Moon will last about 3 months + 2 months follow-up period. Over the course of the study, the study treatment or placebo will be administered as injection, 6 times. It is a drug that targets [include 1-3 sentences on how the drug is believed to work].

Patients are expected to participate in this study for approximately 3 months. During the study, participants will have approximately 15 study visits. Qualified participants may be reimbursed for study-related travel and accommodation costs.

3 months + 2 months follow-up period

treatment or placebo  6 times

15 study visits

How can you help?

Moon is enrolling approximately 120 people with CKD in 20 countries. The success of Moon depends on physicians to refer potential study participants. Your patients may be eligible if they are:

Please note: Other protocol-defined inclusion/exclusion criteria apply.

The study team will check your patient’s full medical history to see if they meet all inclusion criteria and none of the exclusion criteria. Diversity in clinical studies is critical to developing better treatments – help ensure that your patients are represented.

If you have potentially eligible and interested patients, empower them with options and discuss the Moon. You may also contact the nearest study site to refer them.

Find a study site near you!